about
DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriersPDGF-C is a new protease-activated ligand for the PDGF alpha-receptorRNA-seq identifies clinically relevant fusion genes in leukemia including a novel MEF2D/CSF1R fusion responsive to imatinib.A specific requirement for PDGF-C in palate formation and PDGFR-alpha signalingAnalysis of mice lacking the heparin-binding splice isoform of platelet-derived growth factor APDGF-A/PDGF alpha-receptor signaling is required for lung growth and the formation of alveoli but not for early lung branching morphogenesisNo clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.Exploring the link between MORF4L1 and risk of breast cancer.Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer.Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriersEvaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2.Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers.Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general populationDasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006).Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriersLaboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia.Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170.Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factorFunctional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus.Distinct transcriptional control in major immunogenetic subsets of chronic lymphocytic leukemia exhibiting subset-biased global DNA methylation profiles.Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers.Identification of four novel susceptibility loci for oestrogen receptor negative breast cancerCommon variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers.Individuals with FANCM biallelic mutations do not develop Fanconi anemia, but show risk for breast cancer, chemotherapy toxicity and may display chromosome fragility.Use of the BOADICEA Web Application in clinical practice: appraisals by clinicians from various countries.The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium.Mantle cell lymphoma displays a homogenous methylation profile: a comparative analysis with chronic lymphocytic leukemia.Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA.Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia.Bilateral prophylactic mastectomy in Swedish women at high risk of breast cancer: a national survey.U-2973, a novel B-cell line established from a patient with a mature B-cell leukemia displaying concurrent t(14;18) and MYC translocation to a non-IG gene partner.Functional implications of the p.Cys680Arg mutation in the MLH1 mismatch repair proteinComparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study.Whole-genome-amplified DNA as a source for mutational analysis underestimates the frequency of mutations in pediatric acute myeloid leukemia.Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients.High-resolution genomic screening in mantle cell lymphoma--specific changes correlate with genomic complexity, the proliferation signature and survival.
P50
Q21144874-C1C9D854-19D5-409E-B7E8-818AA2879366Q22254096-A0363D71-D132-44D2-9583-6E784961E903Q27852644-40918E08-B179-4E4A-846D-4614612E8C12Q28585038-96FB91CC-7187-435C-A903-CA938A8DC146Q28590608-98159564-EE60-487F-BC0B-15B99B577C45Q28592272-0137E177-E743-47E8-B69B-EB6E859F64B6Q30374367-4E268BCB-A8A5-435E-8ED5-1070FD6812C2Q33646189-3DC47CCD-829E-4F9D-9676-D9FB08A8190EQ33863235-D23FE803-DEFB-4A21-9F56-9EA681DD3EEEQ34081324-17C912CC-F9D2-4E6B-AADB-971E645A9379Q34801008-806255AC-07CC-4D3E-B9FE-86F16C0FF3EEQ34806825-653906DE-E78F-4E3A-9103-F14E1AFA7627Q34949394-CCB145D2-17BB-4AB7-9969-D163A9141D6FQ34963894-0BB11B4F-C0E3-46E2-89C5-995FCA49B30DQ35089479-873F6538-2255-486D-BFB3-45E2E57BEA01Q35194464-150DD09F-B0AE-4DC8-98B3-2216522BCD80Q35523236-235C6B0B-4AA7-45DF-8978-F97DD9D5DA6BQ35603605-932D7DC0-0EBB-4195-AAA3-8E3563268B39Q35870067-EF89264E-E63E-4DD4-BD78-1D72FCC8B7FBQ35940158-46F39F09-6FAB-462A-8271-F14CF02DA853Q35957703-D99431FD-E62B-4795-A1FA-578B8556E1E9Q35999309-E7A173AC-D72C-44B6-83C4-FD92D086FD87Q36124728-ABE57A0A-2D30-4141-B2F2-A52D7BE46E23Q36484147-367C7E50-F4EF-4124-943E-607D9D4477D0Q36839777-1F006783-0419-4435-88C5-C89072194695Q36859142-27D5D4EA-0B59-40A1-9F1E-588169EF7A4FQ37434133-051C89F8-5F84-4948-AB62-B27EA2C83FDCQ38610326-96FF6990-2918-4C68-A29E-C556285AC934Q38721663-8AAFC96D-8C75-46D8-9DAF-E4CCE1F0A419Q38793676-A12989DF-238C-43EE-864B-45F6DBA90320Q39388451-A9114DF5-320A-4203-B115-6487F0DFC7E3Q39665907-9AC22412-890D-4210-8C79-6D61F6CDBA18Q39737827-DED9E599-58F7-4327-9753-8B6784C5BB3DQ39749288-AB42A60D-045C-4C47-89D1-9A314172F920Q39977373-CF3F9429-DA92-44D7-9AAF-61939C14154BQ42752425-7BEC7ACC-E787-45CB-9BE4-BCC6680A2628Q44912433-3F876381-7D46-4B5C-88C5-2EDD817542AFQ45114658-CDDD9B29-6FEB-40D1-8FFC-6880605B159AQ45340032-CA8C9D55-9A0B-4E01-9942-147AE9696993Q45775887-022226D8-33A2-47CD-B6EE-9CB23D2E4852
P50
description
Zweeds onderzoeker
@nl
hulumtues
@sq
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Hans Ehrencrona
@ast
Hans Ehrencrona
@en
Hans Ehrencrona
@es
Hans Ehrencrona
@nl
Hans Ehrencrona
@sl
type
label
Hans Ehrencrona
@ast
Hans Ehrencrona
@en
Hans Ehrencrona
@es
Hans Ehrencrona
@nl
Hans Ehrencrona
@sl
altLabel
Ehrencrona H
@en
Hans Boström
@en
prefLabel
Hans Ehrencrona
@ast
Hans Ehrencrona
@en
Hans Ehrencrona
@es
Hans Ehrencrona
@nl
Hans Ehrencrona
@sl
P214
P1053
M-5619-2014
P106
P21
P214
P27
P31
P3829
P496
0000-0002-5589-3622
P735
P7859
viaf-305841059